GlassScriptPhysician profile
Lawrence D Kimball
NPI 1346248937
$13,988.62
in general payments reported to CMS, 2019-2025
49 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $1,552 · 2021: $2,081 · 2022: $2,226 · 2023: $2,312 · 2024: $2,212 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,506 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,506.37 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,484.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,317.93 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,159.70 | 2021-2025 | |
| Lilly USA, LLC | $1,025.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $998.70 | 2019-2025 | |
| Glaxosmithkline, LLC. | $654.92 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $596.55 | 2022-2025 | Rexulti |
| Amgen INC. | $588.49 | 2019-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $535.95 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $515.89 | 2019-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $463.16 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $462.20 | 2019-2025 | Veozah |
| Allergan, INC. | $459.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $383.72 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.12 | 2019-2025 | Jardiance |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kimball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.